Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06666270 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of SYN818 for the Treatment of Advanced or Metastatic Solid Tumors

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated July 20, 2025 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 1 to 2
    • Start date changed from estimate of Nov 30, 2024 to Nov 21, 2024
    v3
  2. Study title shortened, about 3 wordsv2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This interventional study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of SYN818 as monotherapy in adult patients with advanced solid tumors
Trial Details
NCT Number NCT06666270
Lead Sponsor Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd
Conditions
(from sponsor)		 Advanced Solid Cancer, Metastatic Solid Tumor, Ovarian Cancer, Breast Cancer, Prostate Cancer, BRCA Mutation, HRR Deficiency
Related terms Breast Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Prostatic Neoplasms
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov